FDA Issues To Recall Another Heartburn Drug
FDA Issues To Recall Another Heartburn Drug
Introduction
On April 15, the FDA announced to recall Nizatidine Oral Solution, after finding the presence of the cancer-causing chemical N-Nitrosodimethylamine (NDMA).
Amneal Pharmaceuticals, following the announcement, declared for a nationwide recall of the generic oral heartburn medication nizatidine.
A similar nationwide recall was made on Zantac after the active pharmaceutical ingredient, ranitidine was found to produce high levels of NDMA when in storage. The presence of NDMA in Zantac surfaced in September 2019, when an independent pharmacy found high levels of the carcinogenic chemical in all doses and lots of the widely used heartburn drug.
More than 140 product liability lawsuits and class action cases have been filed throughout the federal court system, each raising similar allegations that the exposure to the active ingredient in Zantac, causes bladder cancer, kidney cancer, colorectal cancer, stomach cancer, and other forms of cancer.
The lawsuits are consolidated and centralized before U.S. District Judge Robin L in Florida under MDL No: 2924, for coordinated discovery and pretrial proceedings.
Latest News
Study Links Roundup Chemical to Long-Term Brain Damage
A recent study suggests that exposure to the widely used herbicide Roundup, which contains the active ingredient glyphosate, may be…
Zimmer Biomet Gets FDA Approval for Cementless Partial Knee
Zimmer Biomet announced it has received supplemental FDA premarket approval (PMA) for the Oxford Cementless Partial…
Court Names Special Masters for Bard Mesh Claim Settlements
The U.S. District Judge overseeing the federal litigation involving Bard hernia mesh lawsuits has appointed two…